Logo image of ALT

ALTIMMUNE INC (ALT) Stock Fundamental Analysis

NASDAQ:ALT - US02155H2004 - Common Stock

3.83 USD
+0.12 (+3.23%)
Last: 8/29/2025, 8:06:11 PM
3.7808 USD
-0.05 (-1.28%)
After Hours: 8/29/2025, 8:06:11 PM
Fundamental Rating

3

Taking everything into account, ALT scores 3 out of 10 in our fundamental rating. ALT was compared to 542 industry peers in the Biotechnology industry. ALT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, ALT is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ALT had negative earnings in the past year.
In the past year ALT has reported a negative cash flow from operations.
ALT had negative earnings in each of the past 5 years.
ALT had a negative operating cash flow in each of the past 5 years.
ALT Yearly Net Income VS EBIT VS OCF VS FCFALT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

ALT has a Return On Assets of -46.10%. This is comparable to the rest of the industry: ALT outperforms 53.51% of its industry peers.
ALT has a better Return On Equity (-54.38%) than 64.39% of its industry peers.
Industry RankSector Rank
ROA -46.1%
ROE -54.38%
ROIC N/A
ROA(3y)-50.39%
ROA(5y)-43.11%
ROE(3y)-56.08%
ROE(5y)-47.74%
ROIC(3y)N/A
ROIC(5y)N/A
ALT Yearly ROA, ROE, ROICALT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

ALT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALT Yearly Profit, Operating, Gross MarginsALT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200K -400K

More info and screens

5

2. Health

2.1 Basic Checks

ALT does not have a ROIC to compare to the WACC, probably because it is not profitable.
ALT has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ALT has been increased compared to 5 years ago.
There is no outstanding debt for ALT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ALT Yearly Shares OutstandingALT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
ALT Yearly Total Debt VS Total AssetsALT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

An Altman-Z score of 2.06 indicates that ALT is not a great score, but indicates only limited risk for bankruptcy at the moment.
ALT has a Altman-Z score of 2.06. This is in the better half of the industry: ALT outperforms 69.74% of its industry peers.
A Debt/Equity ratio of 0.09 indicates that ALT is not too dependend on debt financing.
ALT has a Debt to Equity ratio of 0.09. This is in the lower half of the industry: ALT underperforms 63.65% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Altman-Z 2.06
ROIC/WACCN/A
WACC9.86%
ALT Yearly LT Debt VS Equity VS FCFALT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

ALT has a Current Ratio of 20.44. This indicates that ALT is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of ALT (20.44) is better than 94.28% of its industry peers.
A Quick Ratio of 20.44 indicates that ALT has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 20.44, ALT belongs to the top of the industry, outperforming 94.28% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 20.44
Quick Ratio 20.44
ALT Yearly Current Assets VS Current LiabilitesALT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

4

3. Growth

3.1 Past

ALT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.31%, which is quite good.
Looking at the last year, ALT shows a very negative growth in Revenue. The Revenue has decreased by -95.09% in the last year.
Measured over the past years, ALT shows a very negative growth in Revenue. The Revenue has been decreasing by -67.82% on average per year.
EPS 1Y (TTM)16.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.86%
Revenue 1Y (TTM)-95.09%
Revenue growth 3Y-83.45%
Revenue growth 5Y-67.82%
Sales Q2Q%0%

3.2 Future

ALT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 39.39% yearly.
ALT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 859.66% yearly.
EPS Next Y15.89%
EPS Next 2Y-0.95%
EPS Next 3Y3.76%
EPS Next 5Y39.39%
Revenue Next Year-25%
Revenue Next 2Y7459.66%
Revenue Next 3Y1667.61%
Revenue Next 5Y859.66%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ALT Yearly Revenue VS EstimatesALT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 500M 1B
ALT Yearly EPS VS EstimatesALT Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 20 -20 -40 -60 -80

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ALT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALT Price Earnings VS Forward Price EarningsALT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALT Per share dataALT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.95%
EPS Next 3Y3.76%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALTIMMUNE INC

NASDAQ:ALT (8/29/2025, 8:06:11 PM)

After market: 3.7808 -0.05 (-1.28%)

3.83

+0.12 (+3.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12/bmo
Earnings (Next)11-10 2025-11-10/bmo
Inst Owners47.91%
Inst Owner Change2.47%
Ins Owners0.74%
Ins Owner Change-1.02%
Market Cap338.04M
Analysts78.57
Price Target18.81 (391.12%)
Short Float %29.4%
Short Ratio3.9
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)23.17%
Min EPS beat(2)17.24%
Max EPS beat(2)29.11%
EPS beat(4)4
Avg EPS beat(4)14.25%
Min EPS beat(4)0.21%
Max EPS beat(4)29.11%
EPS beat(8)7
Avg EPS beat(8)12.17%
EPS beat(12)11
Avg EPS beat(12)13.97%
EPS beat(16)14
Avg EPS beat(16)7.16%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.35%
PT rev (3m)-15.61%
EPS NQ rev (1m)16.88%
EPS NQ rev (3m)32.43%
EPS NY rev (1m)15.31%
EPS NY rev (3m)14.05%
Revenue NQ rev (1m)-100%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-48.06%
Revenue NY rev (3m)-99.55%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 16901.79
P/FCF N/A
P/OCF N/A
P/B 2.09
P/tB 2.09
EV/EBITDA N/A
EPS(TTM)-1.18
EYN/A
EPS(NY)-1.37
Fwd EYN/A
FCF(TTM)-0.92
FCFYN/A
OCF(TTM)-0.92
OCFYN/A
SpS0
BVpS1.83
TBVpS1.83
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -46.1%
ROE -54.38%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-50.39%
ROA(5y)-43.11%
ROE(3y)-56.08%
ROE(5y)-47.74%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 20.44
Quick Ratio 20.44
Altman-Z 2.06
F-Score3
WACC9.86%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.86%
EPS Next Y15.89%
EPS Next 2Y-0.95%
EPS Next 3Y3.76%
EPS Next 5Y39.39%
Revenue 1Y (TTM)-95.09%
Revenue growth 3Y-83.45%
Revenue growth 5Y-67.82%
Sales Q2Q%0%
Revenue Next Year-25%
Revenue Next 2Y7459.66%
Revenue Next 3Y1667.61%
Revenue Next 5Y859.66%
EBIT growth 1Y2.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-5.66%
EBIT Next 3Y-19.38%
EBIT Next 5Y13.54%
FCF growth 1Y-14.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-14.65%
OCF growth 3YN/A
OCF growth 5YN/A